Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist licensed by Lilly from Chugai Pharmaceutical
Key facts for understanding the device context: Trial structure: Four or more core trials (TRIUMPH-1 through TRIUMPH-4 plus TRIUMPH-Outcomes), enrolling 5,800 or more participants across programs Administration: Subcutaneous injection, once weekly, dose escalation to 12mg maximum TRIUMPH-4 results (December 2025): Participants on 12mg retatrutide lost an average of 28.7% body weight at 68 weeks, versus 2.1% on placebo (Giblin et al., PMID 41090431) Phase 2 comparison: 24.2% body weight loss at 48 weeks on 12mg (Jastreboff et al., NEJM 2023) - a different trial, shorter duration, earlier data TRIUMPH-Outcomes: Active Phase 3 trial (NCT06383390), estimated 10,000 participants, completion February 2029 - investigating cardiovascular outcomes What the Phase 3 Device Disclosure Gap Means Eli Lilly has not disclosed pen device specifications for retatrutide because the drug is not yet approved, and device details are part of the commercial product launch package
In addition, as seen in Supplementary Fig
Medical Disclaimer: This article is for informational purposes only and is not medical advice
It can happen with weight loss medications, with surgical weight loss, and when people adjust their eating and exercise habits to shed excess pounds
130 Mesenchymal stem cells Mesenchymal stem cells (MSCs) are adult stem cells with potential multidirectional differentiation ability
.png)
